Change of Registered Address
Thalia Therapeutics plc has announced an immediate change to its registered address to 2 Portman Street, London, W1H 6DU. The company, which is developing its proprietary gene delivery system Nuvec® for advanced therapies, made this announcement on April 20, 2026. This administrative update is the sole focus of the RNS release and does not contain any financial performance data or strategic operational changes that would directly impact the stock share price.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it has changed its registered address to 2 Portman Street, London, W1H 6DU with immediate effect.
| Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer | Via Thalia Investor Hub https://investors.thaliatx.com/link/y5RKGe |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)20 7183 2463 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.